Christoph Zielinski
Christoph Zielinski was born in 1952. He studied medicine at the University of Vienna and graduated with an M. D. degree in 1976. During the following two years he worked as a research assistant at the Vienna University Department of Immunology. Subsequently he attended a specialized training in internal medicine at the University Clinic of Gastroenterology and Hepatology. In 1978 he left for a two years fellowship at the Cancer Research Center of the Department of Medicine, Tufts University School of Medicine, Boston, MA, USA.
After returning to Vienna he finished his education in 1983. Three years later he became associate professor of clinical immunology, and in 1989 he was granted a lectorship in the field of internal medicine. Christoph Zielinski is now professor of internistic experimental oncology, deputy head of the Clinical Division of Oncology at the Vienna University Clinic of Internal Medicine I, and vice-dean of the medical school of the Vienna University. Additionally, he is director of the Ludwig Boltzmann Institute of Clinical Experimental Oncology in Vienna.
Professor Zielinski has been working mainly in the fields of oncology, hematology, and clinical immunology. One of the main topics of his research groups is diagnosis and treatment of breast cancer. Professor Zielinski is co-ordinator of the Cooperative Group on Clinical Molecular Oncology and president of the Central European Cooperative Oncology Group (CECOG), a collaboration of academic oncological centers from twelve Central and South-east European countries. Professor Zielinski contributes his experience to the development of the Her-2-specific tumor vaccines HerVac® and MimoVac®, whose most important application will be the treatment of breast cancer.